Whistleblower Can't Fight Amgen's $612M Aranesp Deal: Judge
A New York federal judge on Wednesday denied a whistleblower's bid to challenge Amgen Inc.'s $612 million civil settlement over misbranding its Aranesp anemia drug, part of a combined $762 million...To view the full article, register now.
Already a subscriber? Click here to view full article